Gilead CEO: We’re going to make sure that access is not an issue with remdesivir
On Wednesday Gilead Sciences, best known as a maker of HIV medicines, sent out a 177-word press release that led to a sigh of relief around the world: A study had shown that its experimental drug, remdesivir, had reduced the time it took for patients with Covid-19 to get better.
The data were only preliminary, and many questions still remain, including the nature of the treatment effect in patients. But for Gilead’s chief executive, Daniel O’Day, it was a big moment. O’Day was named as Gilead’s CEO in December 2018, and says he is “humbled” by what the company has accomplished.
